Jan.21.2021
R & D
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer
This material is intended to notify the press release issued on January 20 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please click https://www.bms.com/media/press-releases.html for the original press release.